BioGem
Nov 13, 9:07 AM
$KMTS Anything above
$20 is extremely expensive for this stock. Consider a short here. Critical negatives:
-Revenue growth rate QOQ is slowing down drastically.
-Margins are weak with deep operating losses and without any relief in sight for a few years to come. Profitability is impossible at this rate.
-Cash is consumed away, while they raised capital by adding debt.
-Dilution of the basic shares is at a high rate, and continuous insider sales of stock.
-High short interest = consensus of poor stock.
0 replies